Suppr超能文献

地诺单抗治疗复发性颈椎巨细胞瘤

Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor.

作者信息

Kajiwara Daisuke, Kamoda Hiroto, Yonemoto Tsukasa, Iwata Shintaro, Ishii Takeshi, Tsukanishi Toshinori, Ohtori Seiji, Yamazaki Masashi, Okawa Akihiko

机构信息

Department of Orthopedic Surgery, Chiba Cancer Center, Chiba, Japan.; Department of Orthopedic Surgery, Chiba University, Chiba, Japan.

Department of Orthopedic Surgery, Chiba Cancer Center, Chiba, Japan.

出版信息

Asian Spine J. 2016 Jun;10(3):553-7. doi: 10.4184/asj.2016.10.3.553. Epub 2016 Jun 16.

Abstract

A 43-year-old male patient with C5 giant cell tumor (GCT) underwent tumor resection and anterior bone fusion of C4-C6. The tumor recurred locally 9 months after surgery with the patient complaining of neck and shoulder pain similar to his preoperative symptoms. Denosumab was administered and his pain disappeared after a two-month administration, with a sclerotic rim formation seen at the tumor site on computed tomography. He has been followed for 18 months with no evidence of tumor recurrence. Complete resection is generally recommended, but is not easy for many patients with cervical GCT because of the existence of neurovascular structures. Some patients suffer from recurrence and treatment becomes more difficult. As such, denosumab may be an efficacious option for treatment of recurrent GCT of the cervical spine, although long-term follow-up is required to monitor for presence or absence of recurrence.

摘要

一名43岁的男性C5巨细胞瘤(GCT)患者接受了肿瘤切除及C4 - C6前路骨融合术。术后9个月肿瘤局部复发,患者主诉颈部和肩部疼痛,与术前症状相似。给予地诺单抗治疗,用药两个月后疼痛消失,计算机断层扫描显示肿瘤部位出现硬化边缘形成。对其进行了18个月的随访,无肿瘤复发迹象。一般建议完整切除,但对于许多颈椎GCT患者来说并不容易,因为存在神经血管结构。一些患者会复发,治疗变得更加困难。因此,地诺单抗可能是治疗颈椎复发性GCT的有效选择,尽管需要长期随访以监测是否复发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a959/4917776/7a9e624bb8e1/asj-10-553-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验